Treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study

To evaluate the efficacy of cryopreserved amniotic membrane (CAM) in reducing signs and symptoms of dry eye disease (DED) in a large patient population. A retrospective chart review at 10 clinical sites was done of patients with refractory DED who received CAM and completed at least 3 months of foll...

Full description

Saved in:
Bibliographic Details
Published in:Clinical ophthalmology (Auckland, N.Z.) N.Z.), 2018-01, Vol.12, p.677-681
Main Authors: McDonald, Marguerite B, Sheha, Hosam, Tighe, Sean, Janik, Susan B, Bowden, Frank W, Chokshi, Amit R, Singer, Michael A, Nanda, Seema, Qazi, Mujtaba A, Dierker, Damon, Shupe, Adam T, McMurren, Brittany J
Format: Article
Language:English
Subjects:
Amniotic membrane
Apoptosis
Computer aided manufacturing
Contact lenses
Cyclosporins
Dry eye
Epidemiology
Eye diseases
Eyes & eyesight
Family medical history
Growth factors
Inflammation
Keratitis
Nonsteroidal anti-inflammatory drugs
Ocular Surface
Ophthalmic agents
Ophthalmology
Original Research
Patient outcomes
Patients
Therapeutics
Workshops (Educational programs)
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the efficacy of cryopreserved amniotic membrane (CAM) in reducing signs and symptoms of dry eye disease (DED) in a large patient population. A retrospective chart review at 10 clinical sites was done of patients with refractory DED who received CAM and completed at least 3 months of follow-up. Data collected were demographics; medical history including previous and current ocular treatment, diagnosis, clinical presentations, comorbidity, duration and frequency of treatment with CAM; and concomitant medications. The primary outcome was the change in dry eye workshop (DEWS) score after treatment. A total of 97 eyes of 84 patients exhibited severe dry eye despite maximal medical treatments including topical artificial tears, cyclosporine-A, serum, antibiotics, and steroids. Patients manifested with superficial punctate keratitis (86%), filamentary keratitis (13%), exposure keratitis (19%), neurotrophic keratitis (2%), and corneal epithelial defect (7%). After CAM treatment for 5.4±2.8 days, 74 (88%) patients demonstrated an improved ocular surface along with a notable reduction of the severity as the overall DEWS score was significantly reduced from 3.25±0.5 at baseline to 1.44±0.6 at 1 week, 1.45±0.6 at 1 month, and 1.47±0.6 at 3 months (
ISSN:1177-5467
1177-5483
1177-5483
DOI:10.2147/OPTH.S162203